Leukemia News

Healio | HemOnc Today is excited to announce a new physician leadership structure, which features seven Associate Medical Editors from various subspecialty areas within oncology and hematology.

Kristen M. Hege, MD, is one of those rare individuals who excels at most of her endeavors.

Outpatient hematopoietic stem cell transplantation following targeted antibody-based conditioning appeared safe and feasible among older patients with acute myeloid leukemia or myelodysplastic syndrome, according to study results.

In this edition, novel T-cell therapy effective against common viruses; FDA approves Brukinsa for chronic lymphocytic leukemia; meeting abstracts show inconsistent toxicity reporting and more.

Ponatinib conferred deeper and more durable responses than imatinib in patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia who received either agent in combination with reduced-intensity chemotherapy.

The FDA recently withdrew its emergency use authorization for Evusheld, a combination monoclonal antibody therapy used to prevent COVID-19 among high-risk individuals.

Brexucabtagene autoleucel continued to confer a greater than 70% complete remission rate among adults with relapsed or refractory B-cell acute lymphoblastic leukemia, results from the latest analysis of a pivotal phase 2 study showed.

Researchers at Cold Spring Harbor Laboratory have developed software that correctly deduces continental ancestry from tumor DNA and RNA.

The FDA announced several regulatory actions the past few weeks.

Toxicity reporting in certain abstracts presented in recent years at ASH Annual Meeting and Exposition appeared inconsistent and incomplete, according to a systematic review.